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IS LOW ANTIEPILEPTIC DRUG DOSE EFFECTIVE IN
LONG-TERM SEIZURE-FREE PATIENTS?
Tânia A.M.O. Cardoso1, Fernando Cendes2, Carlos A.M. Guerreiro3
ABSTRACT - Objective: To investigate the value of leaving seizure-free patients on low-dose medication. Method:
This was an exploratory prospective randomized study conducted at our University Hospital. We evaluated the
frequency of seizure recurrence and its risk factors following complete or partial antiepileptic drug (AED)
withdrawal in seizure free patients for at least two years with focal, secondarily generalized and undetermined
generalized epilepsies. For this reason, patients were divided into two groups: Group 1 (complete AED
withdrawal), and Group 2 (partial AED withdrawal). Partial AED withdrawal was established as a reduction of
50% of the initial dose. Medication was tapered off slowly on both groups. Follow-up period was 24 months.
Results: Ninety-four patients were followed up: 45 were assigned to complete (Group 1) AED withdrawal and
49 to partial (Group 2) AED withdrawal. Seizure recurrence frequency after two years follow-up were 34.04%
in group 1 and 32.69% in Group 2. Survival analysis showed that the probability of remaining seizure free at
6, 12, 18 and 24 months after randomization did not differ between the two groups (p = 0.8). Group 1: 0.89,
0.80, 0.71 and 0.69; group 2: 0.86, 0.82, 0.75 and 0.71. The analysis of risk factors for seizure recurrence
showed that more than 10 seizures prior to seizure control was a significant predictive factor for recurrence
after AED withdrawal (hazard ratio = 2.73). Conclusion: Leaving seizure free patients on low AED dose did
not reduce the risk for seizure recurrence. That is, once the decision of AED withdrawal has been established,
it should be complete.
KEY WORDS: epilepsy, antiepileptic drug withdrawal, seizure recurrence, prognosis.
Vale a pena manter baixas doses de droga antiepilética em pacientes com epilepsia controlada?
RESUMO - Objetivo: Investigar o valor da manutenção de baixas doses de medicação em pacientes com
epilepsia controlada. Método: Trata-se de um estudo prospectivo aleatorizado exploratório, realizado em
nosso Hospital Universitário. Nós avaliamos a freqüência de recorrência de crises e os fatores de risco associados
após a retirada parcial ou completa da droga antiepiléptica (DAE), em pacientes com crises controladas por
pelo menos dois anos. Os pacientes foram divididos em dois grupos: Grupo 1 (retirada completa da DAE) e
Grupo 2 (retirada parcial da DAE). Retirada parcial da DAE foi estabelecida como uma redução de 50% da
dose inicial. A medicação foi retirada lentamente nos dois grupos. O período de seguimento foi de 24 meses.
Resultados: Noventa e quatro pacientes foram seguidos: 45 foram selecionados para a retirada completa
(Grupo 1) e 49 para a retirada parcial (Grupo 2). As taxas de recorrência de crises após dois anos de seguimento
foram 34,04% para o Grupo 1 e 32,69% para o Grupo 2. A análise de sobrevivência mostrou que a probabilidade
de permanecer livre de crises aos 6, 12, 18 e 24 meses após a aleatorização não diferiu entre os dois grupos (p
= 0,8). Grupo 1: 0,89, 0,80, 0,71 e 0,69; Grupo 2: 0,86, 0,82, 0,75 e 0,71. A análise dos fatores de risco para
a recorrência de crises demonstrou que mais que 10 crises antes do controle foi significante para a recorrência
após a retirada da DAE (razão de risco = 2,73). Conclusões: A manutenção de baixas doses de medicação em
pacientes com epilepsia controlada não reduz o risco de recorrência de crises. Portanto, caso a decisão de
retirar a DAE tenha sido estabelecida, a retirada deve ser completa.
PALAVRAS-CHAVE: epilepsia, retirada de droga antiepiléptica, recorrência de crises, prognóstico.
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It is widely known that a large majority of epileptic
patients benefit from the use of AED, which usually
bring about prompt seizure remission. Several studies
in newly diagnosed cases of epilepsies, treated with
AED, showed one-year remission rates between 65
and 80%1. Retrospective studies based on general
populations also demonstrate elevated remission
rates in patients who were diagnosed with epilepsy
in the past and treated with AED2,3. Epilepsy, as a
chronic condition, generally demands prolonged AED
treatment, which may produce toxic effects and risks
of morbidity. However, very little is known about the
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real effect of AED on the evolution of epilepsy. The
AED, apparently, do not modify the natural evolution
of the disease but seem to simply suppress seizures
during a vulnerable period4. AED withdrawal is an
inevitable question when prolonged remission is
achieved. The toxicity of prolonged AED use is the
most powerful argument for drug withdrawal5. Te-
ratogenic effect in pregnant women and AED inte-
raction with oral contraceptives should be considered
as well. Concern about weight gain, compromised
osseous metabolism, and reproductive-endocrine
disorders in women should also be addressed.6.
Another important argument in favor of AED inte-
rruption is the implicit stigma associated with its use,
branding the patient as a chronic disease carrier.
Over the past decades, studies conducted on AED
withdrawal after prolonged seizure control in adults
and children demonstrated that a great proportion
of the patients remained seizure free7. Various studies
report the evolution of patients with controlled
epilepsy after complete AED withdrawal, but no data
are available regarding the effectiveness of low AED
doses in these patients. Nevertheless, it is not un-
common to observe patients with controlled seizures
at “subtherapeutic” AED doses. Some authors state
that maybe the seizure threshold increases as the
duration of epilepsy increases, modifying minimal
therapeutic drug level. This is an important issue,
because maintenance of lower AED doses would
guarantee seizure control with reduced drug toxicity.
Nevertheless, patients would have other benefits
such as reduced treatment costs.
The objective of this pilot study is to investigate
the value of leaving seizure-free patients on low-dose
medication.
METHOD
This is an exploratory, randomized, prospective study
that compares the risk of seizure recurrence after total
and 50% partial AED withdrawal in patients with controlled
epilepsy during a follow-up period of two years. This study
was conducted at the Neurology Clinic of our University
Hospital. The initial evaluation as well as the follow-up
was exclusively performed by the first author, at a specific
outpatient clinic. The period for patient inclusion extended
from January 1991 to November 1995.
Patients included in this study were those who had
partial or generalized tonic-clonic seizures (GTCS) and who
have been seizure-free for two years or longer. They must
have 14 years-old or more and be on monotherapy with
AED conventional doses. Epilepsy was defined as the occur-
rence of two or more unprovoked seizures with at least
24 hours between the seizures8. Patients with idiopathic
partial and primary generalized epilepsies as well as acute
symptomatic and single seizure cases were not included
in the study. Patients with confirmed psychiatric diseases
and those with non-compliance were excluded.
The decision to withdraw AED was taken after the pa-
tient was invited to participate in the study and after tho-
roughly discussing the risks and benefits with the patient
and the family. After the patients had agreed to participate
in the study and before randomization, all the patients
and/or their families (in the case of patients under 18 years
of age) signed informed consents. The Ethic Committee
of University of Campinas approved the study.
Patients were then randomly assigned to two groups:
Group 1 – gradual and complete withdrawal within six
months; Group 2 – partial withdrawal of 50% of the AED
dose in two months. The technique of randomization used
was alternating allocation of consecutive patients.
Before initiating withdrawal of the medication, a com-
plete detailed clinical history was obtained in relation to
epilepsy, personal and family antecedents, treatments and
complementary investigations. All patients were subjected
to clinical as well as neurological examinations.
1. Patients and Follow-up - From a total of 136 conse-
cutive patients initially assessed, 117 patients fulfilled the
inclusion criteria, agreed to participate in the study and
were randomized. A group of 18 patients who were
already randomly selected were later excluded because of
inclusion errors: 10 patients due to either non–compliance
or lost follow-up, two patients who later admitted a seizure
control period of less than two years, one patient with
primary generalized epilepsy (diagnosed after his inclusion
in the study), one patient with a non-epileptic seizure (syn-
cope), one patient had a single seizure with status epi-
lepticus, one patient at withdrawal admitted that he was
already on a sub-dose, one patient refused to sign the in-
formed consent and one patient died due to gastro-intes-
tinal cancer. The remaining 99 patients were followed up.
From the 19 patients not included: six of them were
already on a subdose and/or reducing AED dose, five pa-
tients were concerned about the withdrawal and refuse
to participate, four had less than two years of seizure con-
trol, one was a chronic alcoholic with seizures due alcohol
abstinence, one patient had psychiatric antecedents and
probable non-epileptic seizures, one had unclear diagnosis
and one had serious medical condition that required post-
ponement of the procedure.
The follow-up period of each patient began on the
day the AED withdrawal was initiated. However, as com-
parative analysis was being conducted, time zero was con-
sidered as the time at which both groups reached 50% of
the initial AED dose. From this moment onwards, the gro-
ups would differ in relation to interventions and as a result,
comparison would be more reliable. The patients were
followed up until seizure recurrence or for 24 months after
reach 50% AED dose. Therefore, patients who presented
seizure recurrence during withdrawal, while utilizing 75%
of the AED dose were excluded of the comparative analysis.
The main purpose was to assess seizure recurrence.
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Five of the 99 patients that initiated the follow-up were
excluded from the comparative analysis (two from Group
1 and three from Group 2) because they presented seizure
recurrence during withdrawal while utilizing 75% of the
AED dose. Than, the comparative analysis covered a total
of 94 patients and none of the patients were lost during
the follow- up period of two years.
Clinical characteristics of the patients - The clinical and
demographic characteristics of 94 patients included in the
comparative analysis were: Group 1 with 45 patients and
Group 2 with 49 patients; 44 patients were females
(46.81%); 74 patients were white (78.72%). The median
age when withdrawal was initiated was 30.3 years
(minimum = 15 and maximum = 76 years), the median
age at epilepsy onset was 16.9 years (minimum = 0.1 and
maximum = 62 years), the median active epileptic duration
was 10.7 years (minimum = 0.1 anad maximum = 40
years). Seizure control period before withdrawal: 64
patients (68.09%) presented two to three years, 17
patients (18.09%) presented 3 to 4 years and 13 patients
(13.83%) presented 4 years or more.
Recall visits took place every two months during the
withdrawal phase and every four to six months during
the follow-up phase, with telephone calls every six months
to make sure that information regarding seizure recurrence
was reported. All patients were also instructed to phone
the physician in case of seizure recurrence. Precise infor-
mation regarding seizure recurrence and type was obtai-
ned through detailed interviews held with the patient and
whenever possible with witnesses present.
2. Method and rate of withdrawal - Withdrawal began
with a 25% of the total dose and then 25% every two
months until withdrawal was complete for Group 1 (pre-
dicted period of 6months) and up to 50% of the initial
dose for Group 2 (predicted period of 2 months).
According to the commercial preparations available, the
real AED dose administered was as close as possible to
the calculated dose.
3. Epileptic seizures and syndromes - The seizures were
classified according to the revised ILAE Classification of
Epileptic Seizures (1981)9. Classification of the type of
epilepsy was based on the ILAE Classification of Epilepsies
and Epileptic Syndromes (1989)10. A diagnosis of sympto-
matic epilepsy was concluded when an etiological factor
was clearly recognized or when clinical or imaging signs
detected a cerebral lesion that was consistent with a type
of epilepsy. The terms cryptogenic epilepsy were used
when the etiology was unknown. The supposed localiza-
tion of an epileptogenic zone was based on seizure semio-
logy as well as electroencephalographic and imaging fin-
dings. Patients without unequivocal features of focal or
generalized seizures such as those with only GTCS that
occurred exclusively while sleeping and without focal fin-
dings by clinical, imaging or electroencephalographic tests
were classified as undetermined epilepsy (10, 11).
Status epilepticus was defined as more than 30 minutes
of continuous seizure activity or two or more sequential
seizures without full recovery of consciousness between
seizures9,12.
4. Electroencephalogram (EEG) - Electroencephalo-
grams were obtained in accordance with the international
norms related to the “ 10-20 System” electrode placement
and montages recommended by the American EEG
Society13. The exams were always performed utilizing
activation methods (hyperventilation and intermittent
photic stimulation) during wakefulness and whenever pos-
sible, spontaneous sleep.
The EEG was performed in 88 of the 94 patients during
AED withdrawal. Available EEGs performed before AED
withdrawal (90/94 patients) and after withdrawal (92/94
patients) were also assessed.
EEGs were qualitatively analyzed by a team of electro-
encephalographers at the Clinical Neurophysiology Depart-
ment without previous knowledge about the randomiza-
tion of AED withdrawal. In the analysis, the EEG results
were classified as normal versus abnormal. Abnormal EEG
was considered when epileptiform abnormalities and/or
focal or diffuse slowing were present.
After AED discontinuation EEG results were assessed.
It was considered worsening in EEG pattern when epilep-
tiform activity was registered de novo or when it became
abnormal.
5. Family history - Previous family history of epilepsy
or an unprovoked single epileptic seizure that occurred in
first-degree relatives and/or two or more second or third
degree relatives were considered as positive.
6. Imaging exams - A computerized tomography (CT)
was performed on all the patients and magnetic resonance
imaging (MRI) was performed on 78 patients.
7. Epilepsy severity markers - We tabulated the total
number of seizures and number of GTCS before seizure
control; duration of active epilepsy (period between the
first and last seizure before control); previous unsuccessful
attempts at AED withdrawal (excluding abrupt withdra-
wals); number of AED required in monotherapy to control
seizures since the disease onset (to judge effectiveness,
adequate doses of AED were utilized for adequate periods);
previous history of status epilepticus before withdrawal;
maximum seizure frequency before control (Fig. 8 -
evidencing of the region of the body of an arachnoid
granulation evidencing thick bundles of collagen fibers
(arrows) associated to thinner bundles (arrows 1). 1100x
≥ 1/month and < 1/month).
8. AED and serum dosage of AED - The serum dosage
of AED was obtained before initiating withdrawal (with a
100% AED dose) in all but two patients who were on so-
dium valproate. The serum dosage level before initiating
withdrawal did not influence the medical decision con-
cerning withdrawal.
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The results were analyzed utilizing the parameters de-
fined in the literature14 in the following therapeutic ran-
ges: Carbamazepine – 4 to 12ug/ml, Phenytoin – 10 to 20
ug/ml and Phenobarbital - 10 to 40ug/ml.
Daily AED doses and plasma levels range as follows:
carbamazepine 400 to 1400 mg/day (media = 692.7) and
< 1.0 to 12.9ug/ml (media = 6.95), phenytoin 200 to 400
mg/day (media = 295.8) and < 1.0 to 37.4 ug/ml (media =
8.63), phenobarbital 100 to 150 mg/day (media = 101.8)
and 1.0 to 34.6 ug/ml (media = 15.21) and valproate 500
to 1500 mg/day (media = 1000, only two cases).
9. Summary of the recurrence risk factors - Sex, age at
AED withdrawal (up to 30 and above 30 years), age at
onset of epilepsy (up to 12 and above 12 years), family
history of epilepsy, etiology of epilepsy (localized sympto-
matic, localized cryptogenic and undetermined), presence
of deficits on neurological examination, seizure type
(partial or generalized/ secondarily generalized), seizure
control period (between two to three years and three years
or more), EEG, CT, AED used at withdrawal, AED serum
level at withdrawal and the epilepsy severity markers.
Statistical analysis - Statistical methods used took into
consideration the duration of the follow up period, as it
influences the probability of seizure recurrence. Therefore,
the survival analysis was utilized to observe seizure recur-
rence after AED withdrawal. The Kaplan-Meier curves pro-
vided a cumulative probability of remaining seizure free
(non-recurrence or remission) in relation to time. The uni-
variate and multivariate analysis were applied using the
Cox proportional hazard regression model to assess the
prognostic factors affecting seizure recurrence15.
RESULTS
Overall recurrence risk
During the first two years of follow-up, 16 out of
47 patients in Group 1 (34.04%) and 17 out of 52
patients in Group 2 (32.69%) presented seizure re-
currence. Two patients from Group 1 and three pa-
tients from Group 2 presented recurrence while using
75% of the initial AED dosage during the first six
months of follow-up.
The survival analysis of 94 patients who were
subjected to two therapeutic strategies indicating
the time dependent cumulative probability of pa-
tients remaining seizure free is shown in Figure 1.
This cumulative probability of continuing in remission
at 6, 12, 18 and 24 months after initiating drug with-
drawal was 0.89, 0.80, 0.71, 0.69 for Group 1 and
0.86, 0.82, 0.75, 0.71 for Group 2 (Table 1).
Fig 1. Cumulative probability of remaining seizure free following
discontinuation of AED in a 24 months follow-up, in patients
with controlled epilepsy: overall recurrence risk - Kaplan-Meier
survival curves comparing total with partial 50% dose.
Table 1. Cumulative probability of remaining seizure free among
randomized groups after starting AED withdrawal (Survival analysis).
Survival Probability (Proportion of Remission) after starting AED
withdrawal
6 months 12 months 18 months 24 months
Group 1 0.8889 0.8000 0.7111 0.6889
Group 2 0.8571 0.8163 0.7551 0.7143




Fig 2. Cumulative probability of remaining seizure free following
discontinuation of AED in a 24 months follow-up, in patients
with controlled epilepsy: effect of total number of seizures before
control on outcome - Kaplan-Meier survival curves comparing
patients with up to 10 seizures and with more than 10 seizures
before control.
570 Arq Neuropsiquiatr 2003;61(3-A)
Table 2. Univariate analysis of risk factors for seizure recurrence after total or partial AED withdrawal – Cox proportional
hazards regression model.
Recurrence Univariate Model
Variables Yes (%) No (%) Hazard 95% Confidence p-value
Ratio Interval
Withdrawal type
Partial withdrawal 14 28.6 35 71.4
Total withdrawal 14 31.1 31 68.9 1.10 (0.52-2.30) 0.8067
Sex
Female 16 36.4 28 63.6
Male 12 24.0 38 76.0 0.62 (0.29-1.30) 0.2049
Seizure type
Generalized 26 31.0 58 69.1
Partial 2 20.0 8 80.0 0.64 (0.15-2.70) 0.5453
 Total Number of seizures
Up to 10 9 18.4 40 81.6
More than 10 19 42.2 26 57.8 2.72 (1.23-6.01) 0.0137
Number of GTCS
Up to 10 14 22.2 49 77.8
More than 10 14 45.2 17 54.8 2.43 (1.16-5.11) 0.0187
Neurological Examination
Normal 26 30.2 60 69.8
Abnormal 2 25.0 6 75.0 0.73 (0.17-3.08) 0.6704
CT
Normal 10 24.4 31 75.6
Abnormal 18 34.0 35 66.0 1.47 (0.68-3.18) 0.3301
EEG before withdrawal
Normal 13 27.7 34 72.3
Abnormal 14 32.6 29 67.4 1.24 (0.59-2.65) 0.5712
EEG at withdrawal
Normal 19 31.7 41 68.3
Abnormal 9 32.1 19 67.9 1.09 (0.49-2.41) 0.8324
EEG after withdrawal
Normal 11 22.9 37 77.1
Abnormal 17 38.6 27 61.4 1.95 (0.91-4.17) 0.0841
Age at epilepsy onset
Up to12 years 11 30.6 25 69.4
Above 12 years 17 29.3 41 70.7 0.94 (0.44-2.00) 0.8614
Active epilepsy duration
Up to 3 years 5 21.7 18 78.3
More than 3 years 23 32.4 48 67.6 1.42 (0.57-3.49) 0.4512
N. º of AED needed to control seizures
1 14 25.9 40 74.1
2 or more 14 35.0 26 65.0 1.21 (0.57-2.53) 0.6215
Maximal previous seizure frequency
Up to 1/month 14 25.9 40 74.1
More than 1/month 14 35.0 26 65.0 1.50 (0.72-3.16) 0.2807
Continued
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Table 3. Multivariate analysis of risk factors for seizure recurrence
after total or partial AED withdrawal – Cox proportional hazards
regression model.
Multivariate Model





More than 10 2.73 (1.22-6.07) 0.0142
Table 2. Continued.
Recurrence Univariate Model
Variables Yes (%) No (%) Hazard 95% Confidence p-value
Ratio Interval
Previous AED withdrawal attempt
No 22 32.8 45 67.2
Yes 6 22.2 21 77.8 0.68 (0.28-1.68) 0.4073
Age at AED withdrawal
Up to 30 years 15 73.2 41 26.8
Above 30 years 13 65.8 25 34.2 1.29 (0.62-2.72) 0.4971
EEG evolution (worse)
No 18 32.1 38 67.9
Yes 10 33.3 20 66.7 1.02 (0.47-2.21) 0.9618
AED serum level with 100% dose
Therapeutic range or high 22 34.4 42 65.6
Low 5 19.2 21 80.8 0.51 (0.19-1.35) 0.1747
Etiology
Cryptogenic Localized 12 30.8 27 69.2
Symptomatic Localized 14 26.9 38 73.1 0.88 (0.41-1.91) 0.7514
Undeterminate 2 66.7 1 33.3
Family history of seizures
Negative 17 28.8 42 71.2
Positive 11 32.4 23 67.7 1.184 (0.55-2.53) 0.6631
Years of seizure control
2 to 3 years 19 29.7 45 70.3 1.00 (0.45–2.22) 0.9951
More than 3 years 9 30.0 21 70.0
AED
Phenytoin 4 16.7 20 83.3
Carbamazepine 12 29.3 29 70.7 1.95 (0.63-6.04) 0.2479
Phenobarbital 11 40.7 16 59.3 2.90 (0.92-9.12) 0.0683
Valproate 1 50.0 1 50.0 - - -
Risk factors for recurrence
Univariate Analysis: the analysis of the risk factors
for recurrence was performed for the whole popu-
lation sample. Table 2 presents the univariate analysis
of the factors analyzed and their association with a
modified risk of recurrence. The variable status
epilepticus was excluded from the analysis, as the
number of positive cases was small: four positive
cases out of a total of 94 cases. After analyzing all
the factors, only the number of seizures prior to con-
trol presented a correlation with risk of seizure recur-
rence after AED withdrawal: patients who presented
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more than 10 seizures before achieving control (19/
45 – 42.2%) presented a risk 2.72 times greater than
those who presented up to 10 seizures (9/49 – 18.4%)
(p = 0.014; Table 2). Figure 2 demonstrate the survi-
val curves for accumulated remission probability
related to time for patients with up to 10 seizures and
for those with more than 10 seizures before control.
Table 2 demonstrates that no significant change
occurred regarding the risk of seizure recurrence in
relation to the other variables analyzed.
Multivariate Analysis: was performed using the
Cox proportional hazards model and those variables
with p < 0.20 in the univariate analysis were also
included. After AED withdrawal, only the number of
seizures before control once again presented
association with seizure recurrence risk (p = 0.014)
(Table 3).
DISCUSSION
In this study we found that the frequency of sei-
zure recurrence between patients who underwent
partial versus complete AED withdrawal was the sa-
me. The overall recurrence risk presented by both
groups was similar to that found in other studies
and those referred in Berg & Shinnar’s meta-ana-
lysis16: 0.25 and 0.29, respectively, one and two years
after starting AED withdrawal.
It is interesting to note that two studies that asses-
sed seizure recurrence risk in patients with controlled
epilepsy for at least two years maintaining medica-
tion have similar results. The MRC Antiepileptic Drug
Withdrawal Study Group17 reported that the fre-
quency of seizure recurrence in these patients after
a two years period was 22%, and Specchio et al.18
reported a frequency of 18% for the same observa-
tion period.
Among the risk factors for seizure recurrence, only
more than 10 seizures prior to seizure control was
significant for recurrence after AED withdrawal at
the multivariate analysis. Patients who presented mo-
re than 10 seizures before control demonstrated a
risk 2.73 fold greater than those who presented up
to 10 seizures, as verified by the multivariate analysis.
However, it is interesting to note that both the total
number of seizures and the number of GTCS affected
significantly the risk of seizure recurrence at the uni-
variate analysis. That is because there is a co-linearity
between them. This variable, which is an indicator
of seizure severity before control, has been shown
by other studies to be a predictive factor for seizure
recurrence after AED withdrawal19-21. Other studies
have demonstrated that this factor has shown only
a tendency towards significance22,23. Moreover,
others showed no relationship between number of
seizures prior to seizure control and increased
recurrence risk for seizure recurrence after disconti-
nuation of AED24-26. However, the importance of these
studies might be limited to patients at tertiary epi-
leptic centers, since seizures are easily controlled in
a great majority of the patients with recently diag-
nosed epilepsy7.
EEG result was not a risk factor in our study. Ne-
vertheless, studies often present conflicting results
and great variability regarding the EEG characteristics
as well as the manner in which these abnormalities
are reported and classified. Berg and Shinnar’s16 me-
ta-analysis was used to assess 15 studies and al-
though they were substantially heterogeneous, the
relative recurrence risk for patients with abnormal
EEG before AED withdrawal was 1.45 fold that of
the patients with normal EEG, a small but significant
difference. In children, an abnormal EEG before AED
withdrawal is an important predictive factor for
seizure recurrence. In adults, however, the relation-
ship between abnormal EEG and risk of seizure recur-
rence has been established in a lesser degree7.
We also found no difference in the risk for seizure
recurrence when AED withdrawal occurred after a
longer period of seizure control: 2-3 years versus >
3 years (p = 0.99). This observation was in
accordance with most reports in the literature7 and
suggests that a two-year period of seizure control is
sufficient to justify an attempt at AED withdrawal.
The major drawback of our study is the sample
size. Since there is no definite data about the risk of
seizure recurrence in adults with conventional or low
AED dose after a seizure free period of at least two
years, it is difficult to establish the exact sample size
needed to perform this task. Although a larger sam-
ple will be needed to investigate this issue, this would
be very difficult to be accomplished without a mul-
ticenter study.
It is known that there are individuals who benefit
from the maintenance of low AED doses after long
periods of seizure freedom; and the maintenance of
lower AED doses would reduce drug toxicity, adverse
events and treatment costs. However, our study sho-
wed that leaving seizure-free patients on low-dose
medication did not reduce the risk for seizure recur-
rence when compared to patients in which the AED
was completely withdrawn. That is, once the decision
of AED withdrawal has been established, it should
be total. This is a preliminary finding, and a larger
sample is needed to be assessed in order to confirm
these results.
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